Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia

Published:2023-05-11 Issue:8 Volume:72 Page:2769-2782
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Gao Xiao-Ning,Su Yong-Feng,Li Meng-yue,Jing Yu,Wang Jun,Xu Lei,Zhang Lin-Lin,Wang An,Wang Yi-Zhi,Zheng Xuan,Li Yan-Fen,Liu Dai-Hong

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03454-y.pdf

Reference49 articles.

1. Thol F, Ganser A (2020) Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol 21:66. https://doi.org/10.1007/s11864-020-00765-5

2. Burnett AK (2002) Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol 6:26–45. https://doi.org/10.1046/j.1468-0734.2002.00058.x. (Discussion 86–27)

3. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969–1978. https://doi.org/10.1200/jco.2005.06.027

4. Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–494. https://doi.org/10.1200/jco.2010.30.1820

5. Forman SJ, Rowe JM (2013) The myth of the second remission of acute leukemia in the adult. Blood 121(7):1077–1082. https://doi.org/10.1182/blood-2012-08-234492

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia;Frontiers in Immunology;2024-08-16

2. Single-arm clinical trials: design, ethics, principles;BMJ Supportive & Palliative Care;2024-06-04

3. Decrease and impaired function of circulating mucosa-associated invariant T cells in acute myeloid leukemia;2024-03-28

4. Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors;Frontiers in Pharmacology;2024-01-09

5. Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?;Vaccines;2023-12-12